Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands											1 Months Ended							12 Months Ended
	Dec. 08, 2020	Aug. 11, 2020	Jul. 18, 2019	May 19, 2019	May 15, 2019	May 14, 2019	May 07, 2019	Mar. 01, 2019	Aug. 15, 2018	Apr. 04, 2018	Dec. 20, 2019	Aug. 20, 2019	Apr. 29, 2019	Apr. 18, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 02, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 30, 2020	Dec. 24, 2020	Oct. 01, 2020	Jul. 01, 2020	Apr. 15, 2020	Jan. 31, 2020	Jan. 06, 2020	Dec. 13, 2019	Feb. 07, 2019
Stockholders' Equity (Textual)
Common stock shares issued																		32,783,495	15,873,128
Issued shares of common stock							336,000						336,000			60,000
Common stock value issued for services			$ 3									$ 18
Common stock shares issued for services			6,945									45,000
Purchase agreement, description											The Company entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor. Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27 per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock. The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public announcement of positive clinical data results for LO2A.
Warrant exercise price																			$ 0.16
Ownership, percentage																				87.65%								50.00%
Joint venture agreement, description																	Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000 shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics' common stock, which represented a holding percentage less than 5 percent of Cannabic's then outstanding share capital. The joint venture currently has no assets or liabilities and has not started conducting any of its planned operations.
Common stock par value																		$ 0.001	$ 0.001
Additional paid in capital								$ 765										$ 35,110	$ 34,491
Chairman appointment agreement, description												The Company and Mr. Sieczkarek entered into a Chairman Agreement (the "Chairman Agreement") whereby Mr. Sieczkarek shall receive 202,399 restricted stock units ("RSUs") and options to purchase 102,222 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "Chairman Awards"). The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the "Term") and provides that in the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information, non-competition and non-solicitation.
Stock options granted during the vesting period												$ 29
Share-based expense related to RSU's												$ 185						$ 46
Shares issued																									7,500
Company stock grants to its employee related, description		The Company's Board of Directors approved the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each of the other three non-executive directors. The aggregate fair value of these shares of RSUs at grant date issued was $73, and is being recognized over a period of 2 years following August 11, 2020. The Company recognized $34 during the year ended December 31, 2020, as a share-based expense in connection to the RSU's.												The Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019. The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement in December 2019, as of December 31, 2020, all of the options were forfeited.
Contractual term of stock-based grants, description																			The Company and five representative companies and expected term of stock-based grants of 7 years.
Common stockholders amount								$ 765											$ 765
Loss of change in fair value																			501
Weighted average period for non vested optons																		6 months
Rimon Gold And Fisher [Member]
Stockholders' Equity (Textual)
Common stock shares issued																											2,816,196
Stock issuance to consultant related, description				The Company granted to one of its directors certain options exercisable into 30,000 shares of Common Stock with an exercise price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of share-based compensation expense during year ended December 31, 2019.
2012 Plan [Member
Stockholders' Equity (Textual)
Common Stock available for future grant																		40,474
Shares issued																		4,896
2018 Plan [Member
Stockholders' Equity (Textual)
Common stock shares issued									2,500,000									435,053
Issued shares of common stock																		290,222
Common Stock available for future grant																		2,184,813
Unrecognized compensation cost																		$ 3
Share-based expense related to RSU's																		$ 132	337
Description of investments									(i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.
Preferred Class A [Member]
Stockholders' Equity (Textual)
Converted instrument shares							336						336			60
Warrant [Member]
Stockholders' Equity (Textual)
Common stockholders amount																			$ 15
Series A Warrants [Member]
Stockholders' Equity (Textual)
Conversion price																					$ 0.16
Common stock par value																					$ 0.001
Shares issued	3,000,000
Common Stock [Member]
Stockholders' Equity (Textual)
Issued shares of common stock																			900,000
Company stock grants to its employee related, description										The Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $51 and $154 during the year ended December 31, 2020 and 2019, respectively.
Common stockholders amount																			$ 1
2012 Stock Incentive Plan [Member]
Stockholders' Equity (Textual)
Common stock shares issued																		45,370
Common stock par value																		$ 0.001
Options exercisable, term																		10 years
Restricted Stock Units (RSUs) [Member]
Stockholders' Equity (Textual)
Share-based expense related to RSU's																		$ 2	$ 104
Shares issued																						44,050	25,300	25,300		25,300
Stock issuance to consultant related, description					The Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.	The Company issued to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule: 25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.									The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of grant. The aggregate fair value of these RSUs issued was $476. The Company is recognizing this amount ratably over the vesting period of 24 months following March 31, 2019. In connections with the above, on July 25, 2019 (the initial quarterly vesting date) the Company issued 85,000 Common shares to its officers and directors. The Company recognized $132 and $337 during the year ended December 31, 2020 and 2019 respectively.
Company stock grants to its employee related, description		The Company's Board of Directors approved the equity grant of 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company.													1. To grant to each of Company's four directors 100,000 RSUs. The RSUs will vest quarterly over a period of 24 months. 2. To grant to each its officers (Company's Chief executive officer and to Company's Chief financial officer) 140,000 RSU's. The RSU's will vest quarterly over a period of 24 months.
Restricted Stock Units (RSUs) [Member] \| Series A Warrants [Member]
Stockholders' Equity (Textual)
Warrants exercised shares of common stock	3,000,000
Warrant, description																		The warrants issued to certain purchasers from the private placement in December 2019 (the "December 2019 Warrants") and certain investment rights issued on January 2017 (the "Investment Rights") were also adjusted to reflect a reduced exercise price of $0.001 per share (collectively, the "Warrant Adjustments"). As a result of the Warrant Adjustments, on December 29, 2020 an aggregate of 13,332,654 shares of common stock were issued as a result of the exercise of such warrants, each on a cashless basis. Among others, such warrant exercises also included warrants beneficially owned by our Chief Executive Officer, Noam Dannenberg. The difference between the fair value of the warrants before and after the adjustment was recognized as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $327.
Loss of change in fair value	$ 63